Cargando…
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia
BACKGROUND: Plasmodium vivax accounts for about 40% of all malaria infection in Ethiopia. Chloroquine (CQ) is the first line treatment for confirmed P. vivax malaria in the country. The first report of CQ treatment failure in P. vivax was from Debre Zeit, which suggested the presence of chloroquine...
Autores principales: | Teka, Hiwot, Petros, Beyene, Yamuah, Lawrence, Tesfaye, Gezahegn, Elhassan, Ibrahim, Muchohi, Simon, Kokwaro, Gilbert, Aseffa, Abraham, Engers, Howard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584068/ https://www.ncbi.nlm.nih.gov/pubmed/18959774 http://dx.doi.org/10.1186/1475-2875-7-220 |
Ejemplares similares
-
Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia
por: Getachew, Sisay, et al.
Publicado: (2015) -
Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia
por: Mekonnen, Seleshi Kebede, et al.
Publicado: (2014) -
Polymorphisms in chloroquine resistance-associated genes in Plasmodium vivax in Ethiopia
por: Golassa, Lemu, et al.
Publicado: (2015) -
Correction to: Polymorphisms in chloroquine resistance-associated genes in Plasmodium vivax in Ethiopia
por: Golassa, Lemu, et al.
Publicado: (2018) -
Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia
por: Ketema, Tsige, et al.
Publicado: (2009)